Effects of TAK-442, a direct factor XA inhibitor, and fondaparinux on platelet-associated prothrombinase in the balloon injured artery of rats

被引：0
|
作者：
Konishi, N. [1 ]
Katsuhiko, H. [1 ]
Imaeda, Y. [2 ]
Fujimoto, T. [2 ]
Kubo, K. [3 ]
Kawamura, M. [4 ]
机构：
[1] Takeda Pharmaceut Co, Pharmacol Res Labs 1, Osaka, Japan
[2] Takeda Pharmaceut Co, Med Chem Labs, Osaka, Japan
[3] Takeda Pharmaceut Co, Strateg Res Planning, Osaka, Japan
[4] Takeda Global Reaserch & Dev Ctr, TPC Liaison, Lake Forest, IL USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-398
引用
收藏
页码：759 / 759
页数：1
相关论文
共 42 条
  • [21] Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor
    Fujimoto, Takuya
    Imaeda, Yasuhiro
    Konishi, Noriko
    Hiroe, Katsuhiko
    Kawamura, Masaki
    Textor, Garret P.
    Aertgeerts, Kathleen
    Kubo, Keiji
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (09) : 3517 - 3531
  • [22] Antithrombotic and Anticoagulant Profiles of TAK-442, a Novel Factor Xa Inhibitor, in a Rabbit Model of Venous Thrombosis (vol 56, pg 156, 2010)
    Kawamura, M.
    Konishi, N.
    Hiroe, K.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 56 (04) : 439 - 439
  • [23] Safety evaluation of the factor Xa inhibitor TAK-442 in subjects with acute coronary syndromes: phase 2 AXIOM-ACS trial results
    Goldstein, S.
    Bates, E.
    Bhatt, D.
    Holmes, D.
    Kupfer, S.
    Martinez, F.
    Weitz, J.
    Zannad, F.
    Cao, C.
    Spaeder, J.
    EUROPEAN HEART JOURNAL, 2011, 32 : 414 - 414
  • [24] Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux
    Honda, Yuko
    Kamisato, Chikako
    Morishima, Yoshiyuki
    THROMBOSIS RESEARCH, 2016, 141 : 17 - 21
  • [25] Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban
    Kluft, C.
    Meijer, P.
    Kret, R.
    Burggraaf, J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2013, 35 (04) : 379 - 384
  • [26] Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity (vol 47, pg 1398, 2007)
    Graff, J.
    von Hentig, N.
    Misselwitz, F.
    Kubitza, D.
    Becka, M.
    Breddin, H. K.
    Harder, S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (11): : 1368 - 1368
  • [27] EFFECTS OF DABIGATRAN, A DIRECT THROMBIN INHIBITOR, AS COMPARED TO ENOXAPARIN AND THE DIRECT FACTOR XA INHIBITOR, RIVAROXABAN, ON TISSUE FACTOR-INDUCED PLATELET AGGREGATION IN HUMAN PLATELET RICH PLASMA
    van Ryn, J.
    Kink-Eiband, M.
    Hauel, N.
    Priepke, H.
    Wienen, W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 148 - 149
  • [28] Effects of recombinant factor VIIa on the antithrombotic and bleeding time effects of SS457, a direct factor Xa inhibitor, in rats
    Wong, PC
    Pinto, DJ
    Knabb, RM
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) : E65 - E65
  • [29] Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats
    Morishima, Yoshiyuki
    Honda, Yuko
    Kamisato, Chikako
    Tsuji, Naoki
    Kita, Akemi
    Edo, Naoko
    Shibano, Toshiro
    THROMBOSIS RESEARCH, 2012, 130 (03) : 514 - 519
  • [30] Comparison of the effects of heparin and the direct factor Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in adult rats
    Xia, Jingjun
    Zhang, Zhipeng
    Wang, Jialiang
    Zu, Jianing
    Wang, Nanxiang
    Wang, Duanyang
    CONNECTIVE TISSUE RESEARCH, 2015, 56 (06) : 477 - 482
12345